EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies

Jing Pan, Xiaolong Yuan, Haiyang Yu, Ziqi Liu, Shi Chen, Fang Zhu, Yuhua Shang, Shikai Hong, Xinghua Han, Zhengzhi Zhu, Tengchuan Jin, Yueyin Pan und 1 weitere

Journal for ImmunoTherapy of Cancer · 2026-06 · 14 (6) · e014392

DOI: 10.1136/jitc-2025-014392 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.06.2026. Verfasst von Jing Pan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunoconjugates, B7-H1 Antigen, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Anhui Provincial Health Research Project, USTC Research Funds of the Double First-Class Initiative, the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The immunologically “cold” microenvironment of triple-negative breast cancer presents a major obstacle to treatment, conferring resistance to current immunotherapies. Targeting the stimulator of interferon genes (STING) pathway has emerged as a promising strategy to enhance immunotherapy efficacy.

Methods

In this preclinical study, we leveraged a novel integrated approach by employing a B7-H3-targeted dual-payload antibody-drug conjugate (ADC) to induce innate immune responses and reprogram the tumor microenvironment.

Results

Our preliminary results indicated that the dual-payload ADC induces immunogenic cell death, leading to the release of double-stranded DNA and subsequent activation of the cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase-STING pathway in macrophages and dendritic cells. This, in turn, promotes dendritic cell maturation, M1 macrophage polarization, and enhanced T-cell infiltration, effectively converting immunologically “cold” tumors into “hot” ones. Most importantly, the synergistic combination of the dual-payload ADC with immune checkpoint inhibitors (PD-L1 and 4–1BB) not only rapidly bridges innate and adaptive immunity but also elicits a robust long-term immune memory response.

Conclusions

Collectively, these preliminary results demonstrate that the antitumor efficacy of the dual-payload ADC is mediated through STING pathway activation. This insight opens new avenues for enhancing immunotherapy in B7-H3-expressing solid tumors and paves the way for the clinical translation of next-generation ADC designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentImmunoconjugatesB7-H1 AntigenTriple Negative Breast NeoplasmsAnimalsHumansFemaleMicecGAS-STING Signaling PathwayImmunotherapyCell Line, Tumor

Stichwörter der Autor:innen

Antibody-drug conjugates - ADCBreast CancerToll-like receptor - TLRTumor microenvironment - TME

Substanzen

ImmunoconjugatesB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • Department of Medical Oncology, Anhui Provincial Cancer Hospital, Hefei, Anhui, China.
  • Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
  • College of life sciences, Wuhan University, Wuhan, Hubei, China.
  • Department of Research and Development, Anhui Genebiol Biotech. Ltd, Hefei, Anhui, China.
  • Department of Breast Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China zhoushoubingseu@126.com zkdfyyzzz@163.com…

Förderung

  • the Anhui Provincial Health Research Project
  • USTC Research Funds of the Double First-Class Initiative
  • the National Natural Science Foundation of China
  • the Special Research Fund for Discipline Construction on Standardized Management of Myelosuppression, China Anti-Cancer Association
  • the Emerging Tumor Translational Medicine
  • the Strategic Priority Research Program of the Chinese Academy of Sciences

Zitieren

APA

Pan, J., Yuan, X., Yu, H., Liu, Z., Chen, S., Zhu, F., Shang, Y., Hong, S., Han, X., Zhu, Z., Jin, T., Pan, Y., & Zhou, S. (2026). Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies. Journal for ImmunoTherapy of Cancer, 14(6), e014392. https://doi.org/10.1136/jitc-2025-014392

Vancouver

Pan J, Yuan X, Yu H, Liu Z, Chen S, Zhu F, et al. Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies. Journal for ImmunoTherapy of Cancer. 2026;14(6):e014392. doi:10.1136/jitc-2025-014392

BibTeX
@article{Pan2026,
  author = {Pan, Jing and Yuan, Xiaolong and Yu, Haiyang and Liu, Ziqi and Chen, Shi and Zhu, Fang and Shang, Yuhua and Hong, Shikai and Han, Xinghua and Zhu, Zhengzhi and Jin, Tengchuan and Pan, Yueyin and Zhou, Shoubing},
  title = {Igniting cold tumors: reprogramming the tumor immune microenvironment with dual-payload ADCs in combination with PD-L1&4-1BB bispecific antibodies},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {e014392},
  doi = {10.1136/jitc-2025-014392}
}
Kostenlos starten →